C
옵티팜
153710KOSDAQ의료용품 및 기타 의약 관련제품 제조업42.0 / 100
Reference Date: 2026-07-24
Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR raises overvaluation concerns, ROE is below the industry average. Slightly up 3.6% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
OptiPharm operates in multiple sectors including animal disease diagnosis, pharmaceutical development, bacteriophages, Medipig, and VLP vaccines, offering technology-driven services and products. The company differentiates itself through proprietary diagnostic systems, gene-editing technologies for transgenic animal development, and an efficient vaccine production system.
Number of Employees
79people
Average Salary
59.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.184.0Point
PBR
2.68Industry Average 1.090.0Point
2.5x industry avg (risky)
ROE
-9.48Industry Average -4.893.5Point
1.9x industry avg (good)
Debt Ratio
10.79Industry Average 6.860.5Point
1.6x industry avg (risky)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.4% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲4.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -9.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (19%, downtrend)
Current 4,640Won52-week high 6,20052-week low 4,260
1-month return4.0Point
1m +3.57% (slight rise)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-29